In-Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product and Services (Reagents & Kits, Instruments, Data Management Software, Services), By Technology (Immunoassays, Clinical Chemistry, Molecular Diagnostics, Hematology, Microbiology, Coagulation & Hemostasis, Urinalysis, Chromatography & Mass Spectrometry), By Applications (Infectious Diseases, Oncology, Endocrinology, Cardiology, Blood Screening, Genetic Testing, Autoimmune Diseases, Allergy Diagnostics, Drug Monitoring & Testing, Bone & Mineral Disorders, Coagulation Testing, Blood Group Typing, Other Applications), By End-User (Hospital & Clinics, Clinical Laboratories, Home Care Settings, Pharmaceutical & Biotechnology Companies, Other End Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

In-Vitro Diagnostics (IVD) Market Size

The global in-vitro diagnostics market size was valued at USD 115.79 billion in 2024 and is projected to reach from USD 125.45 billion in 2025 to USD 202.91 billion by 2033, growing at a CAGR of 6.19% during the forecast period (2025-2033).

The growth of the in-vitro diagnostics market can be attributed to several key factors, including the increasing demand for rapid diagnostic testing, the rise of point-of-care diagnostics devices, and the growing prevalence of chronic diseases. The popularity of personalized medicine and early diagnosis has further fueled market expansion. Moreover, the COVID-19 pandemic played a significant role in boosting the IVD industry, as major players like F. Hoffmann-La Roche Ltd, bioMérieux, Siemens Healthineers AG, and Abbott Laboratories reported substantial increases in diagnostic revenues during this period.

• For instance, in Q1 2021, amid the third wave of COVID-19, Roche’s diagnostics division experienced an impressive 48% revenue increase compared to Q1 2020, driven by heightened demand for testing solutions. Similarly, bioMérieux reported a 16% revenue growth, with clinical application revenue rising by 24%, largely due to a 67% increase in sales of BIOFIRE molecular biology products in 2020.
• In Q1 2021, clinical sales rose by 10%, bolstered by a 19% increase in BIOFIRE products and a 28% surge in immunoassay sales due to COVID-19 serology tests. However, Q1 2022 saw a slight decline in clinical sales by 2%, alongside stable molecular biology sales and reduced immunoassay sales, as COVID-19 testing demand began to wane.
• By Q1 2024, clinical sales rebounded with a 7% increase, driven by an 18% rise in BIOFIRE molecular biology and a 9% growth in microbiology sales, while immunoassay sales remained steady. This momentum is expected to continue throughout the forecast period, supported by sustained investment and ongoing innovation in the diagnostics sector.

The below table shows a comparison of major players’ Q1 diagnostic revenues across the 2019-2024 period.

Source: Annual Reports, Investor Presentations & Straits Research Analysis

IVD Market Trends

Increasing popularity of personalized medicine and preventive healthcare

The growing emphasis on personalized medicine and preventive healthcare is significantly driving the expansion of the in vitro diagnostics market. This trend enhances the demand for diagnostic tests that can identify specific genetic markers, detect diseases at earlier stages, and monitor the effectiveness of tailored treatments. As personalized medicine becomes more mainstream, the need for advanced IVD solutions that facilitate these targeted approaches increases, prompting greater investment and innovation in the sector.

Healthcare providers and patients alike are increasingly relying on precise and early diagnostic tools to guide treatment decisions and improve clinical outcomes. For instance, numerous biopharmaceutical companies are focused on advancing IVD technologies to support precision medicine initiatives.

A notable example is Illumina, Inc., which launched the TruSight Oncology (TSO) Comprehensive test in March 2022 in Europe. This IVD test profiles 517 cancer-related genes and offers a rapid turnaround time of four to five days for comprehensive tumor gene and biomarker analysis, enabling earlier decisions in precision medicine.

Likewise, in July 2024, Renalytix plc partnered with the Steno Diabetes Center to introduce the AI-powered KidneyIntelX in Europe. This innovative tool integrates biomarker testing into clinical workflows for managing diabetes and chronic kidney disease, underscoring the vital role of IVD in personalized treatment and value-based care.

These advancements highlight the pivotal shift towards personalized healthcare and the growing significance of IVD in enhancing patient outcomes.

In-Vitro Diagnostics Market Drivers

Focus on early disease detection

The emphasis on early disease detection is a critical driver in the in-vitro diagnostics market, significantly enhancing healthcare outcomes while reducing costs. Early detection enables timely intervention, which can prevent disease progression and minimize the need for complex treatments. IVD tools, including blood tests, imaging technologies, and molecular diagnostics, play a vital role in this proactive approach to healthcare.

For instance, 

• Cologuard, developed by Exact Sciences Corporation, is a non-invasive stool DNA test designed for colorectal cancer screening. By detecting abnormal DNA and hemoglobin in stool samples, Cologuard helps identify potential cancerous or precancerous lesions, offering a less invasive alternative to traditional colonoscopies.
• The Afinion HbA1c test from Abbott Laboratories provides rapid and accurate measurements of HbA1c levels, which is crucial for diabetes management. This test delivers quick results, allowing for timely intervention and better management of blood sugar levels.

These examples underscore how IVD tools facilitate early detection, leading to improved health outcomes by enabling prompt and appropriate treatment interventions. By prioritizing early disease detection, it continues to advance healthcare quality and efficiency.

Restraining Factors

Regulatory complexity and stringent approval processes

A significant challenge in the in-vitro diagnostics market is the regulatory complexity and stringent approval processes imposed by governing bodies such as the U.S. FDA and the European Union’s In Vitro Diagnostic Regulation (IVDR). These regulations create hurdles for manufacturers, slowing the pace of innovation and market entry.

For instance,

• The implementation of the European IVDR in 2022 introduced more rigorous certification requirements for IVD products, mandating comprehensive evidence of safety and efficacy. This shift necessitated substantial investments in clinical data and documentation, increasing the burden on manufacturers.
• In the United States, IVD products must comply with additional labeling regulations outlined in 21 CFR 809. After receiving FDA approval, manufacturers are also required to register their products through the FDA Unified Registration and Listing System (FURLS). This process involves annual fees and ongoing administrative obligations, further driving operational costs.

Such regulatory complexities act as significant barriers to market entry, hindering the adoption of advanced diagnostic technologies and limiting the overall growth potential of the IVD industry. Addressing these challenges will be crucial for fostering innovation and expanding access to essential diagnostic tools.

Market Opportunity

Technological advancements in in-vitro diagnostics (ivd) devices

Technological advancements in devices are propelling significant growth in the IVD market by markedly enhancing diagnostic capabilities. Innovations such as automation, the integration of artificial intelligence (AI), and the development of highly sensitive tests are revolutionizing diagnostic practices.

For instance, 

• F. Hoffmann-La Roche Ltd offers automated cobas systems that streamline laboratory workflows by automating various testing processes. This reduces human error and increases testing throughput, resulting in faster and more reliable diagnostic results that can improve patient care.
• Similarly, PathAI provides AI-powered diagnostic tools that analyze digital pathology images with exceptional precision. This integration of AI enhances diagnostic accuracy by assisting pathologists in making rapid and precise cancer diagnoses. As a result, the overall efficiency and effectiveness of cancer detection are significantly improved.

These technological innovations not only accelerate the turnaround time for results but also enhance the overall accuracy and reliability of diagnostic processes. As such, they are fostering the widespread adoption of advanced in-vitro diagnostics solutions across the healthcare sector, ultimately improving patient outcomes and driving market growth.

Regional Insights

North america is a dominant region with 41.79% market share

This leadership is attributed to its highly developed healthcare infrastructure, substantial investments in advanced diagnostic technologies, and an increasing demand for accurate and timely diagnostic solutions. The robust healthcare system in the U.S. and Canada fosters innovation, leading to the rapid development and adoption of new IVD technologies.

For example, companies like Thermo Fisher Scientific have invested heavily in next-generation sequencing and molecular diagnostics, significantly enhancing capabilities for disease detection and monitoring. Moreover, the region's commitment to research and development ensures continuous advancements in diagnostic methods, further solidifying its leading position globally. With a focus on improving patient outcomes and leveraging technology, North America remains at the forefront of the IVD market, setting benchmarks for quality and innovation in healthcare diagnostics.

Asia pacific is the fastest growing region

With countries like China, India, and Australia projected to witness the fastest compound annual growth rate (CAGR) due to surge driven by the rapid development of healthcare infrastructure, a rising prevalence of chronic diseases, and an increasing adoption of advanced diagnostic technologies. For instance, the Indian government has implemented initiatives aimed at expanding healthcare access, such as the Ayushman Bharat program, which enhances funding for healthcare services and promotes the use of diagnostic technologies.

In China, the demand for affordable diagnostics is driving innovation, with companies like China National Pharmaceutical Group (Sinopharm) advancing their diagnostic capabilities. Moreover, Australia’s emphasis on early detection and preventive care is spurring investment in IVD technologies. Collectively, these factors are fostering a conducive environment for market expansion, making the Asia-Pacific region a key player in the global IVD landscape.

Countries insights

• The U.S. accounts for the major share owing to the presence of established major manufacturers, substantial R&D investments in diagnostic technologies, and the high volume of IVD tests performed annually, underscoring the extensive use and critical role of IVD tools in the country’s healthcare system. According to Pew Research, approximately 3.3 billion of IVD tests are carried out annually in the U.S., reinforcing its market dominance in the IVD sector.
• Germany's IVD market is growing owing to the focus on advanced diagnostic technologies along with the growing adoption of AI in the development of advanced diagnostic tests. In addition, focusing on precision medicine, healthcare digitalization, and robust healthcare infrastructure are the major factors driving market growth.
• The UK’s IVD market is largely driven by a strong emphasis on personalized medicine and the adoption of molecular diagnostics, particularly in oncology. For example, the National Health Service (NHS) is instrumental in integrating IVD technologies into routine healthcare, while companies such as Thermo Fisher Scientific and Oxford Nanopore Technologies are advancing innovation in AI-driven diagnostics and early disease detection.
• France’s IVD market is fueled by its commitment to improving public health and expanding healthcare access. Significant factors include the government’s focus on increasing diagnostic testing and integrating advanced technologies into routine care. The growth of point-of-care testing and digital health solutions, supported by companies like bioMérieux, drives market expansion. France’s emphasis on quality diagnostics and healthcare access continues to support the dynamic growth of its IVD market.
• Italy’s IVD market is growing due to government investments in healthcare infrastructure and an increasing focus on advanced diagnostics. In 2021, the market experienced growth supported by the expansion of hospital networks and the adoption of molecular diagnostics. For example, DiaSorin, a key player, is advancing innovative diagnostic solutions. The integration of digital health solutions and ongoing healthcare reforms contribute to Italy’s rising market, enhancing access and quality in diagnostics.
• India's IVD market is propelling owing to the rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and various infectious diseases, resulting in increasing demand for diagnostic tools. According to the International Diabetes Federation 2021, stated that, in India, 74.19 million people suffered from diabetes in 2021, along with projected to increase to 92.97 million by 2030 and further to 124.87 million by 2045, thereby driving the demand for IVD diagnostic tools.
• China’s IVD market is driven by its aging population, increasing demand for self-testing kits, and rise in the number of independent clinical laboratories (ICLs) offering advanced diagnostics tests. According to the Population Reference Bureau, in 2023, China had the largest elderly population, with 167 million people, further propelling the demand for diagnostics.
• Australia’s IVD market is expanding due to advancements in personalized medicine and chronic disease management. Government support for healthcare innovation and a strong regulatory framework underpin this growth. Major players such as CSL Limited are instrumental in developing new diagnostic technologies. Australia’s focus on chronic disease management and personalized care drives the market’s advancement, reflecting its commitment to improving healthcare outcomes.

IVD Market Segmentation Analysis

By product and services

The global market is bifurcated into reagents & kits, instruments, and data management software, and services. The reagents & kits segment holds a dominant position due to their essential role in performing diagnostic tests. These products are crucial for detecting and quantifying biomarkers, pathogens, and other analytes in various samples, making them fundamental to the diagnostic process. For instance, in February 2022, Invitae Corporation launched its first CE-IVD cancer testing kits, FusionPlex Dx and LiquidPlex Dx, in Europe.

These advanced IVD products enhance precision oncology by providing high-quality solutions for cancer detection and management, catering to the growing demand for effective diagnostic tools in the European market. The ongoing innovations and launches in reagents & kits underline their importance in the IVD landscape, driving market growth and expanding the possibilities for personalized medicine and improved patient outcomes.

By technology

The global market is bifurcated into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and chromatography & mass spectrometry. The immunoassays segment leads the industry due to its high accuracy, reliability, and versatility in detecting a wide range of diseases and conditions. Immunoassays are critical for diagnosing infections, cancers, and chronic diseases, utilizing antibody-antigen interactions to deliver precise and sensitive results.

• In February 2023, Epitope Diagnostics, Inc. launched its fully automated chemiluminescent immunoassay analyzers, ECL25 and ECL100, alongside panel kits for routine and specialized tests across various clinical areas. These advancements enhance diagnostic capabilities, streamline workflows, and improve patient care. The growth of the immunoassays segment reflects the increasing demand for accurate diagnostics, propelling innovations and investments in this technology and underscoring its significance in the broader IVD market.

By application

The global market is divided into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The infectious diseases segment dominates the market due to the rising prevalence of infectious diseases like HIV, tuberculosis, and influenza, coupled with the increasing demand for early and accurate diagnostic tests. The need for rapid diagnostics, widespread screening, and government initiatives to control outbreaks further drive this segment's growth.

• In February 2023, Becton, Dickinson and Company received Emergency Use Authorization from the U.S. FDA for a new molecular diagnostic combination test that simultaneously detects SARS-CoV-2, Influenza A & B, and Respiratory Syncytial Virus (RSV). This innovation is crucial for managing respiratory illnesses and highlights the ongoing demand for effective diagnostic solutions in infectious disease management.

By end-user

The global market is divided into hospitals & clinics, clinical laboratories, home care settings, pharmaceutical & biotechnology companies, and other end users. The hospitals & clinics segment holds the largest market share due to high patient volumes, the critical need for diagnostic accuracy, and the extensive use of diagnostic tests across various conditions. Hospitals and clinics are significant investors in advanced IVD technologies to enhance patient outcomes and streamline diagnostic processes.

• In 2023, over 6,146 hospitals in the U.S. relied on IVD tests, underscoring the critical role these tests play in delivering faster and more accurate diagnostic results.

Moreover, the high patient volume and the necessity for precise diagnostics drive significant investments in IVD technologies within this segment, emphasizing its pivotal role in managing patient care and improving healthcare delivery. As hospitals continue to adopt innovative diagnostic solutions, the segment's dominance in the IVD market is set to persist. 

Company Market Share

Key IVD market players are investing in advanced diagnostic technologies and pursuing strategies such as collaborations, acquisitions, and partnerships to enhance their products and expand their market presence.

QuidelOrtho Corporation: An emerging player in the IVD market

QuidelOrtho Corporation is an emerging player in the IVD market, known for its advancements in rapid diagnostic testing solutions. The company focuses on developing innovative assays and platforms for various diagnostic applications, including infectious diseases and chronic conditions.

Recent Developments by QuidelOrtho Corporation

• In August 2024, QuidelOrtho Corporation received U.S. FDA 510(k) clearance for its VITROS syphilis assay. This approval enhances QuidelOrtho’s position as a leading player in the field of infectious disease testing.

Recent Developments

• January 2024- ELITechGroup launched the CE-IVDR certified GI Bacterial PLUS ELITe MGB Kit, enhancing its IVD portfolio with precise detection of major gastrointestinal bacterial pathogens like Campylobacter spp., Clostridium difficile, and Salmonella spp.